profit from every $100 of sales.
$0$100
The Oncology Institute
We have no price for The Oncology Institute since 30 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.05+0.20% today
-53.6% since Oct 13, 25
1-year low $0.041-year high $0.26
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What The Oncology Institute sold, what it kept, and what it did with the cash.
Sales went from $252 million in 2022 to $503 million in 2025, with -$60.6 million of profit last year.
SalesProfit
The Oncology Institute vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| The Oncology Institute | No profit yet | ||
 Tenet Healthcare | 16.2× · Fair price | ||
 Solventum | 9.7× · Cheap | ||
 Encompass Health | 24.4× · Fair price | ||
 Fresenius Medical Care AG & Co. KGaA | 10.6× · Cheap |
AI analysis
An AI analyst reads The Oncology Institute's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 252 | 324 | 393 | 503 | |
| 52 | 60 | 54 | 76 | |
| -72 | -60 | -60 | -36 | |
| 8 | -70 | -51 | -43 | |
| 0 | -83 | -65 | -61 | |
| – | – | – | – | |
| 20.6% | 18.4% | 13.7% | 15.2% | |
| -28.5% | -18.6% | -15.3% | -7.2% | |
| 0.1% | -25.6% | -16.4% | -12.1% |
Balance sheet
| In millions | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 262 | 209 | 173 | 165 |
| Cash | 14 | 33 | 50 | 34 |
| Total debt | 108 | 120 | 123 | 104 |
| Total liabilities | 138 | 152 | 169 | 180 |
| 123 | 57 | 4 | -16 | |
| – | – | – | – | |
| 1.4% | -34.1% | -35.6% | -44.4% | |
| 0.1% | -145.7% | -1,801.7% | 385.5% |
Cash flow
| In millions | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -62 | -36 | -27 | -25 | |
| 6 | 5 | 4 | 3 | |
| -67 | -41 | -30 | -28 | |
| Dividends paid | – | – | – | – |
| 9 | 1 | 0 | – | |
| 28 | 18 | 11 | 5 |
Valuation
- –
- –
- –
- -250.1×
- 0.7×
- –
- –
- -562.9%
- -1.1%
- 0.0%
Profitability
- 15.2%
- -7.2%
- -12.1%
- -4.0%
- -33.8%
- -35.5%
- 326.8%
- -25.9%
- -36.8%
- –
Growth
- +25.8%
- –
- +8.4%
- –
- +93.3%
Financial health
- –
- -1.61
- 15.6%
- -4.3×
- 1.47
- 1.17
- 3.24
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 10%of 964
Bottom 14%of 898
Top 20%of 911
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.02 | -0.09 | +77.1% |
| Mar 12, 2026 | -0.06 | -0.09 | +33.3% |
| Nov 13, 2025 | -0.02 | -0.11 | +85.1% |
| Aug 13, 2025 | -0.18 | -0.12 | −52.1% |
| May 14, 2025 | -0.03 | – | – |
| Sep 30, 2023 | -0.26 | – | – |
| Jun 30, 2023 | -0.23 | – | – |
| Mar 31, 2023 | -0.41 | – | – |
News
Where Will Jazz Pharmaceuticals Be in 5 Years? Oncology Is Becoming Its Growth EngineYahoo Finance · Oct 27, 2026Champions Oncology signals fiscal 2027 momentum as Q1 revenue reaches $15.2M and gross margin improves to 50%Seeking Alpha · Sep 10, 2026SA Asks: What are the most promising oncology companies right now?Seeking Alpha · Aug 22, 2026Citius Oncology GAAP EPS of -$0.08 beats by $0.11, revenue of $1.5M misses by $4.27MSeeking Alpha · Aug 17, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
11No pass
Benjamin Graham
17No pass
Philip Fisher
29No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
11No pass
Terry Smith
16No pass
Questions about The Oncology Institute
Is The Oncology Institute a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the The Oncology Institute AI analysis
What does The Oncology Institute do?
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. It is in Medical - Care Facilities.
Does The Oncology Institute pay a dividend?
No. The Oncology Institute does not pay a dividend at the moment.
Who are The Oncology Institute's competitors?
The largest listed companies in the same industry are Tenet Healthcare, Solventum, Encompass Health and Fresenius Medical Care AG & Co. KGaA. The peers table on this page compares their profit, growth and price with The Oncology Institute's.
Prices: daily closes to Jul 30, 2026. Fundamentals: company reports via invest-like data.